AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
190% more first-time investments, than exits
New positions opened: 380 | Existing positions closed: 131
5% more funds holding
Funds holding: 3,444 [Q3] → 3,610 (+166) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 1,470 | Existing positions reduced: 1,380
6% more call options, than puts
Call options by funds: $3.18B | Put options by funds: $2.99B
1.08% less ownership
Funds ownership: 73.3% [Q3] → 72.22% (-1.08%) [Q4]
9% less capital invested
Capital invested by funds: $256B [Q3] → $234B (-$22.3B) [Q4]
19% less funds holding in top 10
Funds holding in top 10: 206 [Q3] → 166 (-40) [Q4]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$190
10%
downside
Avg. target
$219
4%
upside
High target
$240
13%
upside
10 analyst ratings
8 positive
80%
2 neutral
20%
0 negative
0%
Wells Fargo Mohit Bansal 48% 1-year accuracy 13 / 27 met price target | 13%upside $240 | Overweight Maintained | 5 Mar 2025 |
B of A Securities Tim Anderson 46% 1-year accuracy 6 / 13 met price target | 5%upside $223 | Neutral Maintained | 4 Mar 2025 |
Citigroup Geoff Meacham 63% 1-year accuracy 19 / 30 met price target | 2%upside $215 | Buy Maintained | 3 Feb 2025 |
Truist Securities Srikripa Devarakonda 46% 1-year accuracy 16 / 35 met price target | 3%upside $217 | Buy Maintained | 3 Feb 2025 |
UBS Navin Jacob 0 / 0 met price target | 10%downside $190 | Neutral Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 51 articles about ABBV published over the past 30 days
Positive
Seeking Alpha
3 hours ago
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million upfront for GUBamy, with potential milestones up to $1.875 billion, and royalties on net sales. Amylin analogs like GUBamy offer promising weight loss effects (albeit not at the levels of leading incretin therapies), with potentially much better GI tolerability, lean mass preservation and cardiovascular safety.
Positive
Zacks Investment Research
9 hours ago
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Neutral
CNBC Television
1 day ago
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber
The Investment Committee debate the latest Calls of the Day.
Neutral
The Motley Fool
1 day ago
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.
Negative
Zacks Investment Research
2 days ago
Why AbbVie (ABBV) Dipped More Than Broader Market Today
In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.
Positive
Market Watch
2 days ago
Stocks beating the stock market's recent Trump slump have this in common
This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.
Neutral
Seeking Alpha
2 days ago
AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ET Company Participants Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - EVP, Research & Development, Chief Scientific Officer Scott Reents - Executive Vice President, Chief Financial Officer Rob Michael - Chief Executive Officer Conference Call Participants David Risinger - Leerink Partners David Risinger All right. Good morning, everybody.
Neutral
Accesswire
2 days ago
Siri & Glimstad Defeats AbbVie's Motion to Dismiss Illinois GIPA Lawsuit
Call to Action: Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging that AbbVie violated the Illinois Genetic Information Privacy Act ("GIPA"). In Henry v.
Positive
The Motley Fool
3 days ago
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales.
Positive
Schwab Network
5 days ago
Darst's Stock Picks: GOLD, EL, ABBV
"We currently advise gradually shifting exposure away from high-growth areas toward more value and defensive sectors," notes David Darst. He discusses finding opportunities in an uncertain market.
Charts implemented using Lightweight Charts™